Seguir
Daniela J Conrado
Daniela J Conrado
e-Quantify
E-mail confirmado em e-quantify.com
Título
Citado por
Citado por
Ano
Machine learning in drug discovery and development part 1: a primer
A Talevi, JF Morales, G Hather, JT Podichetty, S Kim, PC Bloomingdale, ...
CPT: pharmacometrics & systems pharmacology 9 (3), 129-142, 2020
572020
Validation of rapid and simple LC–MS/MS method for determination of voriconazole in rat plasma
BV Araujo, DJ Conrado, EC Palma, T Dalla Costa
Journal of Pharmaceutical and Biomedical analysis 44 (4), 985-990, 2007
532007
Pharmacokinetic evaluation of LASSBio‐579: an N‐phenylpiperazine antipsychotic prototype
DJ Conrado, H Verli, G Neves, CAM Fraga, EJ Barreiro, SMK Rates, ...
Journal of Pharmacy and Pharmacology 60 (6), 699-707, 2008
492008
The effect of critical illness on drug distribution
D Gonzalez, D J Conrado, U Theuretzbacher, H Derendorf
Current pharmaceutical biotechnology 12 (12), 2030-2036, 2011
452011
Consistency of drug–drug and gene–drug interaction information in US FDA-approved drug labels
DJ Conrado, HL Rogers, I Zineh, MA Pacanowski
Pharmacogenomics 14 (2), 215-223, 2013
412013
Open innovation: Towards sharing of data, models and workflows
DJ Conrado, MO Karlsson, K Romero, C Sarr, JJ Wilkins
European Journal of Pharmaceutical Sciences 109, S65-S71, 2017
372017
An updated Alzheimer’s disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM
DJ Conrado, WS Denney, D Chen, K Ito
Journal of pharmacokinetics and pharmacodynamics 41, 581-598, 2014
372014
Dopamine transporter neuroimaging as an enrichment biomarker in early Parkinson's disease clinical trials: a disease progression modeling analysis
DJ Conrado, T Nicholas, K Tsai, S Macha, V Sinha, J Stone, B Corrigan, ...
Clinical and Translational Science 11 (1), 63-70, 2018
362018
The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson’s disease
D Stephenson, D Hill, JM Cedarbaum, M Tome, S Vamvakas, K Romero, ...
Journal of Parkinson's disease 9 (3), 553-563, 2019
322019
Model‐informed development and registration of a once‐daily regimen of extended‐release tofacitinib
M Lamba, MM Hutmacher, DE Furst, A Dikranian, ME Dowty, D Conrado, ...
Clinical Pharmacology & Therapeutics 101 (6), 745-753, 2017
292017
Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose–response analysis
DJ Conrado, S Krishnaswami, S Shoji, S Kolluri, J Hey-Hadavi, ...
Journal of pharmacokinetics and pharmacodynamics 43, 325-341, 2016
282016
Open data revolution in clinical research: opportunities and challenges
MH Shahin, S Bhattacharya, D Silva, S Kim, J Burton, J Podichetty, ...
Clinical and Translational Science 13 (4), 665-674, 2020
242020
Genome‐wide association approach identified novel genetic predictors of heart rate response to β‐blockers
MH Shahin, DJ Conrado, D Gonzalez, Y Gong, MT Lobmeyer, ...
Journal of the American Heart Association 7 (5), e006463, 2018
212018
A Markov Chain Model to Evaluate the Effect of CYP3A5 and ABCB1 Polymorphisms on Adverse Events Associated with Tacrolimus in Pediatric Renal …
SKB Sy, J Heuberger, S Shilbayeh, DJ Conrado, H Derendorf
The AAPS journal 15, 1189-1199, 2013
192013
Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats
L Cruz, E Assumpção, SF Andrade, DJ Conrado, IC Kulkamp, ...
European journal of pharmaceutical sciences 40 (5), 441-447, 2010
192010
Microencapsulation of sodium alendronate reduces drug mucosal damage in rats
L Cruz, E Assumpção, SF Andrade, DJ Conrado, SS Guterres, ...
Drug delivery 17 (4), 231-237, 2010
192010
Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581
G Neves, M Kliemann, AH Betti, DJ Conrado, L Tasso, CAM Fraga, ...
Pharmacology Biochemistry and Behavior 89 (1), 23-30, 2008
192008
Development of a model‐based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy
K Lingineni, V Aggarwal, JF Morales, DJ Conrado, D Corey, C Vong, ...
CPT: Pharmacometrics & Systems Pharmacology 11 (3), 318-332, 2022
182022
Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy
DJ Conrado, J Larkindale, A Berg, M Hill, J Burton, KR Abrams, ...
Journal of pharmacokinetics and pharmacodynamics 46, 441-455, 2019
172019
Molecular neuroimaging of the dopamine transporter as a patient enrichment biomarker for clinical trials for early Parkinson's disease
K Romero, D Conrado, J Burton, T Nicholas, V Sinha, S Macha, ...
Clinical and Translational Science 12 (3), 240-246, 2019
162019
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20